






ICH Q7 Chapter 15: Complaints & Recalls



PDA - PIC/S
ICH Q7 Training 01/2014



ICH Q7 Training
Chapter 15: Complaints & Recalls



Disclaimer

- The slides set is based on the training sessions developed and performed by the members of the ICH Q7 Expert Working Group (EWG) on ICH Q7 2001/2002
- The slides have been updated 2012 and represents the views of the PDA / PIC/S committee for the purposes of a general training for regulators and industry.
- ◆ *We focused on elements in ICH Q7 where further explanation and/or clarification is useful.*

Connecting People, Science and Regulation®

2



Complaints & Recalls

- **All quality related complaints recorded and investigated according to written procedure (15.10)**
- **Complaint records retained to evaluate (15.12)**
 - Trends
 - Frequencies
 - Severity



Complaint

- **Complaint records (15.11)**
 - Name/address of complainant
 - Name/phone of submitter
 - Nature of complaint includes batch number
 - Date received
 - Action initially taken include what/when/who
 - ◆ *A root cause investigation should be performed and recorded*
 - Follow up action
 - Response to originator
 - Final decision on batch
 - ◆ *All these documents have to be easily available to have the full*



Recall - For clarification

- ◆ *A recall is any withdrawal of an API (not a dosage form) from the supply chain having left the control of the manufacturer*
- ◆ *If the API did not enter the market as a drug (medicinal) product the authorities normally not need to be informed (consider local regulations)*



Recalls

- **Written procedure should describe**
 - When recall should be considered (15.13)
 - Who involved in evaluating information (15.14)
 - How recall initiated (15.14)
 - Who should be informed of recall (15.14)
 - How recalled material is treated ◆ *and traced* (15.14)
- ◆ *It is helpful to describe reconciliation procedures*



Recalls

- **Serious or potentially life-threatening situation – local / national / international authorities informed (15.15)**
 - ◆ *Communication channels should be considered (e.g. health authorities, traders, senior management, business, country affiliates)*
 - ◆ *In case of limited experience it has been shown beneficial to simulate a recall situation in order to verify the system to be effective*



Key Messages

- **Investigations are recorded**
- **Corrective actions and preventive actions should be implemented (effective CAPA system)**
- **The system must be confirmed to be efficient and meet timelines**
- **Authorities are informed appropriately by the marketing authorisation holder (following local requirements)**



Acknowledgement

- **This version represents an update of the 2001/2002 version by ICH Q7 EWG members organised in a joint initiative between PDA and PIC/S developed in 2012**
 - Stephan Rönninger (co-chair)
 - Mikael Le Bihan (co-chair)
 - Karl-Heinz Bender
 - Rosimeire Pereira Alves da Cruz
 - Graeme McKilligan
 - Jacques Morenas
 - Edwin Rivera
 - Georg Roessling
 - Lionel Viornerywith input from members of the PIC/S Q7 expert cycle and other PDA volunteers

